United States: Celgene Notches Rare Win On PTAB Request For Rehearing

Last Updated: September 28 2017
Article by Jason Mock

The recent decisions of the USPTO Patent Trial and Appeal Board (PTAB) granting Celgene's requests for rehearing in parallel Inter Partes Review proceedings brought by Kyle Bass's Coalition for Affordable Drugs (CFAD) are notable in several respects. First, the fact that the PTAB granted rehearing and partially reversed its original rulings is a rare success for a patent owner. Second, the fact that Celgene was able to uphold one of the challenged claims highlights the potential value of obtaining a variety of claims and defending them on an individual basis.

The Celgene Patent At Issue

The decisions at issue were rendered in three parallel IPRs: Affordable Drugs VI, LLC, v. Celgene Corporation (IPR2015-01098, IPR2015-01102, and IPR2015-01103). The patent at issue in all three proceedings was Celgene's U.S. 6,315,720, which is directed to methods of "delivering" (distributing) teratogenic drugs (such as Thalidomide) in a way that restricts access to patients that have an acceptable risk profile. Independent claim 1 recites:

  1. In a method for delivering a drug to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by said drug, wherein said method is of the type in which prescriptions for said drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber is registered in said medium and qualified to prescribe said drug, that the pharmacy is registered in said medium and qualified to fill the prescription for said drug, and the patient is registered in said medium and approved to receive said drug, the improvement comprising:
    defining a plurality of patient risk groups based upon a predefined set of risk parameters for said drug;
    defining a set of information to be obtained from said patient, which information is probative of the risk that said adverse side effect is likely to occur if said drug is taken by said patient;
    in response to said information set, assigning said patient to at least one of said risk groups and entering said risk group assignment in said medium;
    based upon said information and said risk group assignment, determining whether the risk that said adverse side effect is likely to occur is acceptable; and
    upon a determination that said risk is acceptable, generating a prescription approval code to be retrieved by said pharmacy before said prescription is filled.

Claim 10, which is the only claim for which Celgene requested rehearing recites that the information set upon which a determination is made includes genetic testing results.

The Final Written Decisions

The final written decisions held all claims invalid as obvious over certain THALOMID" prescribing information in view of Cunningham (U.S. 5,832,449) and further in view of the knowledge of one of ordinary skill in the art. The PTAB additionally relied on the testimony of CFAD's expert, Dr. Fudin, and his interpretation of FDA meeting minutes that discussed genetic counseling for pregnant women. Based on the combined references and the other evidence of record, the PTAB held with respect to claim 10 "that the genetic testing of dependent claim 10 represents a combination of known elements for their known use to achieve a predictable result."

The PTAB Request For Rehearing Decision

Celgene requested rehearing, asserting the PTAB erred in finding claim 10 obvious. Specifically, Celgene alleged that CFAD had not provided sufficient evidence to prove that genetic testing for the claimed purpose was "common," as CFAD's alleged, and that the PTAB impermissibly shifted the burden onto Celgene to show that genetic testing was not known in the art for the claimed purpose.

In a rare move, the PTAB granted Celgene's requests for rehearing, and admitted its error:

We agree that the proper focus is not whether Patent Owner disputed that fact, but whether Petitioner came forward with evidence sufficient to demonstrate that genetic testing was known and would have been used in the combination required by claim 10. We also agree that the lack of disclosure in the prior art of record—coupled with the record's disclosure of other types of tests—cuts against a finding "that genetic testing would be used, let alone that it would have been common."

Perhaps the PTAB had seen the Federal Circuit decision in Honeywell, which reversed the Board for improperly shifting the burden to the patent holder on a different issue.

Thus, the PTAB ultimately held that CFAD did not demonstrate that claim 10 was unpatentable, and the final written decision for each of the IPRs was modified to hold that only claims 1-9 and 11-32 are unpatentable.


It is no secret that the odds of succeeding on a PTAB request for rehearing are extremely long. Hundreds of requests for rehearing have been filed since the AIA took effect, and only a handful have been granted. However, cases like this show that if a party is able to articulate a clear error in legal analysis–rather than simply a disagreement with the way in which the evidence was weighed–the PTAB may acknowledge its mistake and reverse an earlier holding. In order to identify errors that may provide a solid basis for a request for rehearing, parties may want to take careful note of the PTAB's articulated rationales in both its institution decisions and its final written decisions. While requests for rehearing may rarely reap reward, when they do, the reward can be great.

As noted above, this case also highlights the potential value of obtaining a variety of claims. The patent at issue included two independent claims, with 26 claims dependent from claim 1 and four claims dependent from claim 28. While preserving 1 claim out of 32 might not sound like a good result, if that one claim encompasses relevant products, it could have significant commercial value.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions